Comment
doi: 10.1016/S1473-3099(21)00697-6. Epub 2021 Nov 23.SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines
Affiliations
- PMID:34826382
- PMCID: PMC8610239
- DOI: 10.1016/S1473-3099(21)00697-6
Item in Clipboard
Comment
SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines
Ramachandran Thiruvengadam et al. Lancet Infect Dis.2022 Mar.
Display options
Format
Display options
Format
No abstract available
Conflict of interest statement
We declare no competing interests.
Comment on
- Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.Desai D, Khan AR, Soneja M, Mittal A, Naik S, Kodan P, Mandal A, Maher GT, Kumar R, Agarwal A, Gowda NR, H V, Kumar P, Pandey S, Pandey RM, Kumar A, Ray A, Jorwal P, Nischal N, Choudhary A, Brijwal M, Madan K, Lodha R, Sinha S, Dar L, Wig N, Guleria R.Desai D, et al.Lancet Infect Dis. 2022 Mar;22(3):349-356. doi: 10.1016/S1473-3099(21)00674-5. Epub 2021 Nov 23.Lancet Infect Dis. 2022.PMID:34826383Free PMC article.Clinical Trial.
References
- WHO . World Health Organization; Geneva: 2021. Evaluation of COVID-19 vaccine effectiveness.
- Government of India Ministry of Health and Family Welfare Co-WIN dashboard: India COVID-19 vaccination status. 2021.https://dashboard.cowin.gov.in/
- Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021 doi: 10.1016/S0140-6736(21)02000-6. published online Nov 11. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous